OQS
DSGN icon

Occudo Quantitative Strategies’s Design Therapeutics DSGN Stock Holding History

Occudo Quantitative Strategies’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,395
Closed -$94.3K – 813
2024
Q1 		$94.3K Buy
23,395
+11,071
+90% +$29.6K 0.02% 656
2023
Q4 		$32.7K Sell
12,324
-88,398
-88% -$202K ﹤0.01% 741
2023
Q3 		$238K Buy
+100,722
New +$470K 0.03% 746
2023
Q2 		– Sell
-12,652
Closed -$73K – 1073
2023
Q1 		$73K Buy
+12,652
New +$94.6K 0.01% 837

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Occudo Quantitative Strategies's DSGN Position: Q2 2024 in Review

Occudo Quantitative Strategies sold out of Design Therapeutics (DSGN) in Q2 2024, closing a stake of 23,395 shares — an estimated $94.3K sold.

Occudo Quantitative Strategies first reported a position in DSGN in Q1 2023 and held it in 4 quarters. The position peaked at $238K in Q3 2023. 95 funds tracked by Wall St. Rank hold DSGN as of Q2 2024.

  • Occudo Quantitative Strategies reported no remaining Design Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 23,395 Design Therapeutics shares in Q2 2024, an estimated $94.3K.
  • Occudo Quantitative Strategies first reported a position in Design Therapeutics in Q1 2023 and held it in 4 quarters.
  • Occudo Quantitative Strategies's Design Therapeutics position peaked at $238K in Q3 2023.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.